Evidence mapPaperPMID 39077521Full record

ReviewReviews in cardiovascular medicine2023

High-Throughput Metabolomics Applications in Pathogenesis and Diagnosis of Valvular Heart Disease.

Daniel W Mutithu, Jennifer A Kirwan, Henry A Adeola, Olukayode O Aremu, Evelyn N Lumngwena, Lubbe Wiesner, Sebastian Skatulla, Richard Naidoo, Ntobeko A B Ntusi

Abstract readReview
In one paragraph

Review in Reviews in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel W MutithuDivision of Cardiology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, 7925 Cape Town, South Africa.
Jennifer A KirwanMetabolomics Platform, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Henry A AdeolaHair and Skin Research Laboratory, Division of Dermatology, Department of Medicine, University of Cape Town, 7925 Cape Town, South Africa.
Olukayode O AremuDivision of Cardiology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, 7925 Cape Town, South Africa.
Evelyn N LumngwenaDivision of Cardiology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, 7925 Cape Town, South Africa.
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, 7925 Cape Town, South Africa.
Sebastian SkatullaComputational Continuum Mechanics Research Group, Department of Civil Engineering, Faculty of Engineering and the Built Environment, University of Cape Town, 7925 Cape Town, South Africa.
Richard NaidooDivision of Anatomical Pathology, Department of Pathology, University of Cape Town, and National Health Laboratory Services, 7925 Cape Town, South Africa.
Ntobeko A B NtusiDivision of Cardiology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, 7925 Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-throughput metabolomics techniques are a useful tool to understand many disease conditions including cardiovascular disease such as valvular heart disease(s) (VHD). VHD involves damage to heart valves, mostly presenting as stenosis, regurgitation or prolapse and can be classified into degenerative, rheumatic, congenital, or prosthetic valve disease. Gaps remain in our understanding of the pathogenesis of the common VHD. It is now fitting to place into perspective the contribution of metabolomics in the mechanism of development, diagnosis, and prognosis of VHD. A structured search for metabolomics studies centred on human VHD was undertaken. Biomarkers associated with the pathogenesis of bicuspid aortic valve disease, mitral valve disease, rheumatic heart disease, and degenerative aortic valve stenosis are reviewed and discussed. In addition, metabolic biomarkers reported to prognosticate patient outcomes of post-valve repair or replacement are highlighted. Finally, we also review the pitfalls and limitations to consider when designing metabolomics studies, especially from a clinician's viewpoint. In the future, reliable and simple metabolic biomarker(s) may supplement the existing diagnostic tools in the early diagnosis of VHD.

Indexed as

degenerative valve diseasemass spectrometrymetabolomicsrheumatic valve diseasevalvular heart disease

Identifiers

PMID39077521
PMCPMC11264134

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.